The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats

Diabetes and Vascular Disease Research

Volumn 7, Issue 2, 2010, Pages 138-144

  Murthy, Subramanyam N ^a   Hilaire, Rose Claire St ^a   Casey, David B ^a   Badejo, Adeleke M ^a   McGee, Jennifer ^a   McNamara, Dennis B ^a   Kadowitz, Philip J ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Carotid injury; Diabetes; Exenatide; Insulin resistance; Intimal hyperplasia; Pair feeding.

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; SODIUM CHLORIDE; TRANSCRIPTION FACTOR RELA; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; NOS3 PROTEIN, RAT; PEPTIDE; RELA PROTEIN, RAT; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; BODY WEIGHT; CAROTID ARTERY; CONTROLLED STUDY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; AORTA; CAROTID ARTERY INJURY; DRUG EFFECT; DRUG POTENTIATION; EATING; ENZYMOLOGY; HYPERPLASIA; INTIMA; METABOLISM; PATHOLOGY; ZUCKER RAT;

ANIMALS; AORTA; CAROTID ARTERY INJURIES; EATING; FEMALE; HYPERPLASIA; INSULIN RESISTANCE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDES; RATS; RATS, ZUCKER; RECEPTORS, GLUCAGON; TRANSCRIPTION FACTOR RELA; TUNICA INTIMA; VENOMS;

EID: 77954491096     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109360269     Document Type: Article

References (31)

1. Grundy, S.M., Benjamin, I.J., Burke, G.L., et al. (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134-46.
2. Sowers, J.R., Frolich, E.D. (2004) Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 88: 63-82.
3. Ludwig, S., Shen, G.X. (2006) Statins for diabetic cardiovascular complications. Curr Vase Pharmacol 4: 245-51.
4. Wilson, P.W.F., Meigs, J.B. (2008) Cardiometabolic risk: a Framingham perspective. Int J Obes (Lond) 32: S17-S20.
5. Devici, E., Yesil, M., Akinci, B., et al. (2009) Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol 32: 32-6.
6. Hamnvik, O.P., McMahon, G.T. (2009) Glycemic targets for patients with type 2 diabetes mellitus. Mt Sinai J Med 76: 227-33.
7. Drucker, D.J. (2007) The role of gut hormones in glucose homeostasis. J Clin Invest 117: 24-32.
8. Ban, K., Noyan-Asraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117: 2340-50.
9. Chia, C.W., Egan, J.M. (2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93: 3703-16.
10. Lovshin, J.A., Drucker, D.J. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5: 262-9.
11. Wei, Y., Mojsov, S. (1995) Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBSLett 30: 358: 219-24.
12. Bullock, B.P., Heller, R.S., Habener, J.F. (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-78.
13. Drucker, D.J. (2006) The biology of incretin hormones. Cell Metabolism 3: 153-165.
14. Orskov, C, Rabenhoj, L., Wettergren, A., Kofod, H, Hoist, J.J. (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-9.
15. Sonne, D.P., Engstrom, T., Treiman, M. (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-l(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146: 243-9.
16. Abu-Hamdah, R., Rabjee, A., Meneilly, G.S., Shannon, R.P., Andersen, D.K., Elahi, D. (2009) Clinical review: The extra-pancreatic effects of GLP-1 and related peptides. J Clin Endocrinol Metab 94: 1843-52.
17. Drucker, D.J., Nauck, M.A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl pepti- dase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-705.
18. Mafong, D.D., Henry, R.R. (2008) Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 10: 55-60.
19. Timmers, L., Henriques, J.P., de Kleijn, D.P., et al. (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-10.
20. Laugero, K.D., Stonehouse, A.H., Guss, S., Landry, J., Vu, C, Parkes, D.G. (2009) Exenatide improves hypertension in a rat model of the metabolic syndrome. Metab Syndr Relat Disord 7: 327-34.
21. Hodis, H.N., Mack, W.J., LaBree, L., et al. (1998) The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128: 262-69.
22. Linhart, A., Garlepy, J., Massonneau, M., Dauzat, M. (2000) Carotid intima-media thickness: the ultimate surrogate end-point of cardiovascular involvement in atherosclerosis. Appl Radiol 29: 25-39.
23. Park, S., Marso, S.P., Zhou, Z., Foroudi, F., Topoi, E.J., Lincoff, A.M. (2001) Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104: 815-19.
24. Murthy, S.N., Chandra, S., McGee, J. (2008) Exenatide reduces carotid intimal hyperplasia in balloon catheter injured Zucker fatty rats. ADA, San Francisco, CA.
25. McNamara, D.B., Murthy, S.N., Fonseca, A.N., Desouza, C.V., Kadowitz, P.J., Fonseca, V.A. (2009) Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. Can J Physiol Pharmacol 87: 37-50.
26. Desouza, C.V., Murthy, S.N., Diez, J. (2003) Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Therapeut 8: 297-305.
27. Murthy, S.N., Obregon, D.F., Chattergoon, N.N., et al. (2005) Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation and intimal hyperplasia in Sprague Dawley rats fed a high methionine diet. Metabolism 54: 645-52.
28. Smith, P.K., Krohn, R.I., Hermanson, G.T., et al. (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
29. van Greevenbroek, M.M., Vermeulen, V.M., de Bruin, T.W. (2004) Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. J Lipid Res 45: 1148-54.
30. Chatagnon, A., Bougel, S., Perriaud, L., Lachuer, J., Benhattar, J. and Dante, R. (2009) Specific association between the methyl-CpG-binding domain protein 2 and the hypermeth- ylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis 30: 28-34.
31. Mikhail, N. (2008) Incretin mimetics and dipeptidyl pepti- dase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin InvestigDrugs 17: 845-53.